GLP-1 Science
Weight Loss Medicine and Migraine Frequency
A small pilot study found a GLP-1 medication roughly halved monthly migraine days in people with obesity, independent of...
Among the more unexpected findings in GLP-1 research is a possible effect on tobacco use, discovered somewhat accidentally as researchers examined broader outcome data in people taking these medications for diabetes and obesity. It deserves an honest, appropriately cautious treatment.
What the real-world data found
A target trial emulation study published in the Annals of Internal Medicine in 2024 examined nationwide electronic health records for over 222,000 patients with type 2 diabetes and tobacco use disorder. Comparing new semaglutide users against patients started on seven other diabetes medications, semaglutide use was associated with a significantly lower risk of medical encounters for tobacco use disorder and fewer prescriptions for smoking-cessation medications, cutting relative risk by roughly a third compared with insulin.
What smaller controlled trials found
A phase 2a randomised trial enrolled daily smokers not actively trying to quit and gave them either once-weekly semaglutide or placebo for nine weeks. Participants receiving semaglutide showed greater reductions in nicotine craving and body weight than those on placebo. Notably, the trial did not find a significant reduction in cigarettes smoked per day, and participants were not receiving counselling or nicotine replacement alongside the medication.
The proposed mechanism
GLP-1 receptors are present in brain regions involved in reward processing, the same general pathway thought to underlie reduced "food noise" and cravings covered in our related guide. The hypothesis is that GLP-1 receptor activation dampens reward-driven craving broadly, not specifically for food, which would explain effects across substances including nicotine and, in separate research, alcohol.
Why this evidence should be read carefully
The real-world study is observational, not a randomised controlled trial. It used a rigorous statistical design to approximate one, but association is not the same as proven causation, and unmeasured differences between people prescribed semaglutide versus other medications could partly explain the finding.
The controlled trial was small and short, 9 weeks with a limited sample, and did not show a clear reduction in actual cigarettes smoked, only craving. This is a meaningfully different, weaker finding than a demonstrated quitting benefit.
No GLP-1 medication is approved for smoking cessation by any regulator. This remains investigational, and dedicated trials specifically designed to test smoking cessation as a primary outcome are still ongoing.
What this means practically today
If you smoke and are also considering GLP-1 treatment for weight or metabolic reasons, a possible secondary reduction in cravings is a reasonable thing to be aware of, but it should not be the reason you start treatment, nor should you rely on it in place of established smoking cessation approaches, nicotine replacement, counselling or approved cessation medications, which have a much larger evidence base specifically for this purpose.
Where this applies to sublingual products
This research relates specifically to pharmaceutical semaglutide, and GLP-1 pathway support delivered as drops has not been studied for any effect on smoking or nicotine craving. METASLIM™ is a physician-reviewed sublingual supplement working on the GLP-1 appetite pathway for weight management, and it should not be considered or used as a smoking cessation aid.
See what's included in the program for what it is actually designed and studied to support.
The summary
Real-world data found semaglutide associated with significantly lower risk of tobacco use disorder-related medical care compared with other diabetes medications, though this is observational evidence, not a randomised trial.
A small controlled trial found reduced nicotine craving with semaglutide but no significant reduction in actual cigarettes smoked per day over nine weeks.
The proposed mechanism involves GLP-1's effect on reward pathways broadly, which may explain effects across substances beyond food alone.
This remains early-stage, investigational evidence, not an approved use, and should not replace established smoking cessation methods.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.